All In Biotech

Investigational drug · Phase 2

FF-10832

Also called: Gemcitabine Liposome

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Urothelial Carcinoma, Advanced Non Small Cell Lung Cancer.

Phase 2

Last checked: Nov 19, 2026Latest source record: Sep 4, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

23

Any phase or sponsor naming "FF-10832"

First trial start

2022

Jun 1, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "FF-10832", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Advanced Urothelial Carcinoma
  • Advanced Non Small Cell Lung Cancer

Approved drugs for the same conditions: Small cell lung cancer · Bladder and urothelial cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "FF-10832" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 5 on PubMed

Also in development for Advanced Urothelial Carcinoma

  • AdabelimumabSHR-A2102, SHR2554Phase 320 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma

  • 9MW2821Phase 311 trials

    Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer

  • SYS6002Phase 35 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · Urothelial Carcinoma, Cervical Cancer, Advanced Solid Tumors

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.